Breaking News Instant updates and real-time market news.

RHHBY

Roche

$29.46

0.11 (0.37%)

, BMY

Bristol-Myers

$50.05

0.71 (1.44%)

08:15
10/19/16
10/19
08:15
10/19/16
08:15

Roche Tecentriq approval increases competition, says Leerink

Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.

RHHBY

Roche

$29.46

0.11 (0.37%)

BMY

Bristol-Myers

$50.05

0.71 (1.44%)

MRK

Merck

$62.09

0.57 (0.93%)

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 11

    Nov

RHHBY Roche
$29.46

0.11 (0.37%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
BMY Bristol-Myers
$50.05

0.71 (1.44%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.09

0.57 (0.93%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

, SPX

S&P 500

14:13
09/20/17
09/20
14:13
09/20/17
14:13
Technical Analysis
Technical View: S&P 500 slips below the pivot low »

The S&P 500 (SPX) is…

SPY

SPDR S&P 500 ETF Trust

$249.89

-0.08 (-0.03%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZRX

PhaseRx

$0.78

0.055 (7.64%)

14:11
09/20/17
09/20
14:11
09/20/17
14:11
Hot Stocks
PhaseRx confirms receipt of FDA orphan drug designation for PRX-ASL »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$49.34

0.24 (0.49%)

14:10
09/20/17
09/20
14:10
09/20/17
14:10
Hot Stocks
Sanofi reports 'potential breakthrough' in preclinical work on HIV antibodies »

Researchers working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SPX

S&P 500

14:06
09/20/17
09/20
14:06
09/20/17
14:06
General news
Fed details plans to being reducing balance sheet »

The Federal Reserve said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$14.06

0.29 (2.11%)

14:05
09/20/17
09/20
14:05
09/20/17
14:05
Options
Valeant call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

, SPX

S&P 500

14:04
09/20/17
09/20
14:04
09/20/17
14:04
General news
Federal Reserve maintains median projection for year-end funds rate at 1.4% »

The Fed's "dot…

SPY

SPDR S&P 500 ETF Trust

$249.87

-0.1 (-0.04%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

14:02
09/20/17
09/20
14:02
09/20/17
14:02
General news
Fed says economic activity rising moderately this year »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$68.25

-0.24 (-0.35%)

, SYMC

Symantec

$34.16

0.39 (1.15%)

14:02
09/20/17
09/20
14:02
09/20/17
14:02
Periodicals
Breaking Periodicals news story on Splunk, Symantec »

Symantec 'play'…

SPLK

Splunk

$68.25

-0.24 (-0.35%)

SYMC

Symantec

$34.16

0.39 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SPX

S&P 500

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
Fed plans to initiate balance sheet normalization in October »

The Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:01
09/20/17
09/20
14:01
09/20/17
14:01
General news
FOMC Meeting Announcement Federal Funds Rate data reported »

FOMC Meeting Announcement…

14:00
09/20/17
09/20
14:00
09/20/17
14:00
General news
Breaking General news story  »

Federal Reserve leaves…

RNVA

Rennova Health

$0.22

-0.0021 (-0.93%)

13:55
09/20/17
09/20
13:55
09/20/17
13:55
Conference/Events
Rennova Health to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MLCO

Melco Resorts & Entertainment

$23.78

0.77 (3.35%)

13:50
09/20/17
09/20
13:50
09/20/17
13:50
Options
Bullish option play opened in Melco Resorts as shares tick to 52-week highs »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

, UNH

UnitedHealth

$195.34

0.69 (0.35%)

13:48
09/20/17
09/20
13:48
09/20/17
13:48
Periodicals
McConnell intends to consider healthcare bill in Senate next week, WSJ says »

A spokesman for Senate…

MOH

Molina Healthcare

$62.33

0.21 (0.34%)

UNH

UnitedHealth

$195.34

0.69 (0.35%)

CNC

Centene

$90.10

0.32 (0.36%)

WCG

WellCare

$166.10

-2.065 (-1.23%)

CI

Cigna

$181.44

-0.07 (-0.04%)

ANTM

Anthem

$181.90

0.46 (0.25%)

HNT

Health Net

HUM

Humana

$238.58

-1.46 (-0.61%)

AET

Aetna

$154.56

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

JCI

Johnson Controls

$40.12

1.075 (2.75%)

13:45
09/20/17
09/20
13:45
09/20/17
13:45
Options
Johnson Controls call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
09/20/17
09/20
13:45
09/20/17
13:45
General news
Breaking General news story  »

FOMC Forecasts to be…

13:45
09/20/17
09/20
13:45
09/20/17
13:45
General news
FOMC Meeting Announcement Federal Funds Rate to be reported at 14:00 »

FOMC Meeting Announcement…

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:35
09/20/17
09/20
13:35
09/20/17
13:35
Hot Stocks
Breaking Hot Stocks news story on JAKKS Pacific »

JAKKS Pacific expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
09/20/17
09/20
13:35
09/20/17
13:35
General news
NY Fed accepted $168.03 B in daily reverse repos »

NY Fed accepted $168.03 B…

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:33
09/20/17
09/20
13:33
09/20/17
13:33
Hot Stocks
JAKKS Pacific expects to sustain net loss, negative EPS for the year »

JAKKS still expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$34.95

0.1 (0.29%)

13:33
09/20/17
09/20
13:33
09/20/17
13:33
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

13:32
09/20/17
09/20
13:32
09/20/17
13:32
Hot Stocks
JAKKS Pacific doesn't see LT material adverse impact from Toys 'R' Us filing »

JAKKS Pacific announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$9.14

-0.12 (-1.30%)

13:30
09/20/17
09/20
13:30
09/20/17
13:30
Options
Flurry of activity in Blackberry as shares rally »

Flurry of activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATVI

Activision Blizzard

$64.31

0.11 (0.17%)

13:29
09/20/17
09/20
13:29
09/20/17
13:29
Recommendations
Activision Blizzard analyst commentary  »

Activision launch of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWN

Southwestern Energy

$6.07

0.09 (1.51%)

13:25
09/20/17
09/20
13:25
09/20/17
13:25
Options
Southwestern Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.